title: Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer.
abstract: Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4'deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4'deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.
authors: Department of Medicine, Kaplan Cancer Center, NYU Medical Center.
authors: M D
authors: MD
authors: Green
authors: J L
authors: JL
authors: Speyer
authors: J C
authors: JC
authors: Wernz
authors: N
authors: N
authors: Colombo
authors: U
authors: U
authors: Beller
authors: F M
authors: FM
authors: Muggia
authors: E M
authors: EM
authors: Beckman
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; C030851:esorubicin